Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

WORD

HTML

519

Figures (1-5)

Sum=703

Publishing Process of This Article

Item

Count

Browse

Download

124

Sum=211

Feb 6, 2024 (publication date) through May 22, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Feb 6, 2024; 12(4): 820-827
Published online Feb 6, 2024. doi: 10.12998/wjcc.v12.i4.820

Full Size Figure Download Figure

Figure 5 Variation in cancer antigen 199 levels during second-line treatment.

Citation: Zhou JH, Yi QJ, Li MY, Xu Y, Dong Q, Wang CY, Liu HY. Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report. World J Clin Cases 2024; 12(4): 820-827
URL: https://www.wjgnet.com/2307-8960/full/v12/i4/820.htm
DOI: https://dx.doi.org/10.12998/wjcc.v12.i4.820